Gynecologic Cancer

Top Story

Younger age predicts worse survival from low-grade serous carcinoma of ovary, peritoneum

August 31, 2015

Women aged 35 or younger with low-grade serous carcinoma of the ovary or the peritoneum, as well as those with persistent disease upon therapy completion, have worse survival outcomes than older women with the same cancers, according to observational study results.

Further, patients with low-grade serous carcinoma of the peritoneum (LGSPC) appear to have a better prognosis than patients with low-grade serous carcinoma of the ovary (LGSOC).

Alberta L. Wang In the Journals

Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin

August 28, 2015
Patients with cancer who had a history of presumed carboplatin- and oxaliplatin-induced hypersensitivity reaction did not appear allergic to the chemotherapy drugs after…
In the Journals

Nonselective beta-blockers may improve survival for patients with epithelial ovarian cancer

August 25, 2015
The use of nonselective beta blockers appeared to improve survival among patients with epithelial ovarian cancer, according to results of a multicenter…
Gary H. Lyman, MD, MPH, FASCO, FRCP(Edin) CommentaryPublication Exclusive

Back to the future: Chemotherapy dosing in overweight and obese patients with cancer

HemOnc Today, August 25
Gary H. Lyman, MD MPH
Early in the history of modern cancer chemotherapy, treatment efficacy as well as toxicity were found to demonstrate a clear dose–response relationship for most…
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
4131332248001 th

Antibody-drug conjugate shows promise for NSCLC, ovarian cancer

June 12, 2014
CHICAGO — Howard A. Burris, MD, chief medical officer at the Sarah Cannon Research Institute, offers his…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
David M. Gershenson, MD In the Journals

Younger age predicts worse survival from low-grade serous carcinoma of ovary, peritoneum

August 31, 2015
Women aged 35 or younger with low-grade serous carcinoma of the ovary or the peritoneum, as well as those with persistent disease upon therapy…
Alberta L. Wang In the Journals

Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin

August 28, 2015
Patients with cancer who had a history of presumed carboplatin- and oxaliplatin-induced hypersensitivity reaction did not appear allergic to the…
In the Journals

Nonselective beta-blockers may improve survival for patients with epithelial ovarian cancer

August 25, 2015
The use of nonselective beta blockers appeared to improve survival among patients with epithelial ovarian cancer, according to results of a…
Gary H. Lyman, MD, MPH, FASCO, FRCP(Edin) CommentaryPublication Exclusive

Back to the future: Chemotherapy dosing in overweight and obese patients with cancer

HemOnc Today, August 25
Gary H. Lyman, MD MPH
Early in the history of modern cancer chemotherapy, treatment efficacy as well as toxicity were found to demonstrate a clear dose–response…
Lorenzo Cohen, PhD

Stress and cancer: Mindfulness is pivotal component to improve outcomes

August 24, 2015
Stress hormones are released when the body responds to physical, mental or emotional pressures.These stress hormones — such as epinephrine and…
In the Journals

Black women face worse endometrial cancer outcomes regardless of tumor type

August 20, 2015
Non–Hispanic black women with endometrial cancer experienced worse outcomes than women in other racial and ethnic groups diagnosed with the…

MedImmune acquires Inovio HPV cancer treatment for $700 million

August 15, 2015
Inovio Pharmaceuticals has begun collaboration and sold the exclusive rights to an HPV types 16 and 18 vaccine to MedImmune, the biologics research…
In the Journals

Chemotherapy plus bevacizumab extends survival in epithelial ovarian cancer

August 14, 2015
The addition of chemotherapy to bevacizumab improved survival among women with recurrent, heavily pretreated epithelial ovarian cancer, according to…
Jason D. Wright, MD

Power morcellation: What you should know

August 6, 2015
The FDA issued a warning in late 2014 about the use of power morcellators to treat uterine fibroids.Eight months later, the debate about the safety…
Charis Eng, MD, PhD In the Journals

Risk calculator an accurate, cost-effective prescreening tool for PTEN mutations

July 30, 2015
The PTEN Cleveland Clinic score appeared to be a cost-effective prescreening tool to identify patients with Cowden-like disease who are appropriate…
More Headlines »
morganatic-roan
morganatic-roan